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Introduction {#sec1}
============

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which infects the lungs, leading to fever, cough, and dyspnea ([@bib24]). Most patients presenting with mild disease develop an efficient immune response ([@bib56]), but some go on to develop acute respiratory distress syndrome, leading to admission to the intensive care unit (ICU), often culminating in multi-organ dysfunction and death ([@bib64]).

In addition to cell-autonomous effects of the viral infection, a dysregulated immune response participates in the sudden deterioration of COVID-19 patients, ultimately overwhelming infected and non-infected tissues ([@bib59]). This overt inflammatory response centers around a cytokine storm ([@bib10]) with elevated blood concentrations of interleukin-6 (IL-6). Accordingly, therapeutic agents targeting the IL-6/IL-6R-gp130 axis can alleviate the inflammatory response ([@bib41]) and ameliorate immune dysregulation ([@bib22]), emphasizing the clinical significance of this cytokine. Marked lymphocytopenia is also associated with COVID-19 severity ([@bib10]); however, the primary source of the cytokine storm and of the mechanisms behind lymphocytopenia remains elusive ([@bib36]).

A growing body of evidence points to dysregulation of innate immune cells of the granulomonocytic lineage during viral infections of the lungs. A variety of human viruses infect monocytes and macrophages to spread through the tissues ([@bib2]; [@bib14]; [@bib43]; [@bib52]; [@bib67]). SARS-CoV-2 mRNA is detectable in lung monocytes/macrophages of severe COVID-19 patients ([@bib6]), but its ability to enter these cells in the peripheral blood and activate them directly remains unclear. Also, tissue damage induced by SARS-CoV-2 infection may lead to release of pathogen- and damage-associated molecular patterns that, in turn, induce activation and recruitment of inflammatory cytokine- and chemokine-producing innate immune cells in an amplifying loop ([@bib37]).

It remains unclear to what extent immune patterns associated with COVID-19 pathophysiology are causative and exacerbate the disease and/or could be used for accurate patient stratification. Here, using high-dimensional single-cell approaches, including single-cell RNA sequencing, mass cytometry, and 25-parameter spectral flow cytometry, we show that patients who develop severe disease exhibit a massive release of S100A8/S100A9 calprotectin accompanied by changes in monocyte and neutrophil subsets. We further discover that this pathological immune system reorganization is initiated by onset of emergency myelopoiesis, which release immature myeloid cells with an immunosuppressive phenotype into the peripheral blood and lungs. Our study integrates frequencies of non-classical monocytes and immature neutrophils with calprotectin plasma levels as robust biomarkers of COVID-19 severity and suggests potential therapeutic strategies targeting calprotectin to alleviate severe COVID-19.

Results {#sec2}
=======

Introduction to the Patient Cohort {#sec2.1}
----------------------------------

This non-interventional study enrolled 158 patients ([Table S1](#mmc1){ref-type="supplementary-material"}), including 86 and 72 subjects referred to the hospital with various flu-like symptoms who were diagnosed or not with COVID-19 based on positive and negative RT-PCR of pharyngeal swabs, respectively. Patients were stratified according to disease severity. Mild disease (n = 27) was defined as having no or limited clinical symptoms and not requiring computed tomography (CT) scanning or hospitalization. Moderate disease (n = 16) was defined as being symptomatic, with dyspnea and radiological findings of pneumonia upon thoracic CT scan, requiring hospitalization with a maximum of 9 L/min of oxygen. Severe disease (n = 43) was defined as respiratory distress requiring admission into the ICU. Mild and moderate cases were mixed in the discovery part of the study and considered separately to explore the ability of a routine flow assay to discriminate patients who require hospitalization.

Circulating Innate Immune Cells in Patients with Mild and Severe COVID-19 Exhibit Distinct Phenotypes {#sec2.2}
-----------------------------------------------------------------------------------------------------

To explore changes in circulating immune cell phenotype induced by SARS-CoV-2 infection, we first collected peripheral blood samples from a discovery cohort of 13 patients positive for SARS-CoV-2 (hereafter called COVID-19 patients) by RT-PCR and 12 patients suffering from flu-like symptoms but negative for SARS-CoV-2. The former group included 5 patients with mild disease and 8 patients with severe COVID-19 ([Table S2](#mmc1){ref-type="supplementary-material"}). After red blood cell lysis, we labeled peripheral blood cells with a panel of 25 antibodies recognizing immune cell surface markers ([Key Resources Table](#sec4.1){ref-type="sec"}) and analyzed them by spectral flow cytometry ([Figures 1](#fig1){ref-type="fig"} A, [S1](#figs1){ref-type="fig"} A, and S1B). By pooling the data from the 25 control and COVID-19 patients and subjecting them to dimensionality reduction using the non-supervised Uniform Manifold Approximation and Projection (UMAP) for dimension reduction algorithm ([@bib5]), we identified populations of CD4^+^ T cells, CD8^+^ T cells, CD19^+^ B cells, CD14^High^ monocytes, and CD15^+^CD66b^+^ neutrophils ([Figures 1](#fig1){ref-type="fig"}B and 1C). We also identified HLA-DR^High^CD11b^+^ and CD16^High^ monocytes as well as neutrophils expressing CD11b, CD15, CD16, and CD64 ([Figures 1](#fig1){ref-type="fig"}B and 1C). Analysis and visualization, using UMAP dimensionality reduction to the cell surface marker expression datasets from control and mild and severe COVID-19 groups suggested differences in the repartition of cell populations ([Figure 1](#fig1){ref-type="fig"}D).Figure 1Spectral Flow Analysis of Peripheral Blood Cells in a Learning Cohort of Controls and COVID-19 Patients(A) Peripheral blood sample collection pipeline.(B) Non-supervised UMAP analysis of data from 25 patients (controls, 12; mild, 5; critical, 8).(C) Cell surface marker expression in the UMAP analysis shown in (B).(D) Non-supervised UMAP analysis of patient blood samples in the control, mild, and severe groups.(E) Percentage of neutrophils among total cells in each individual sample in the indicated patient groups.(F) Partition of neutrophil subsets, based on CD101 and CD10 expression, in each patient group (data pooled per group).(G) Percentage of CD10^Low^CD101^+/−^ neutrophils among total neutrophils as in (E).(H) Percentage of monocytes among total cells as in (E).(I) Partition of monocyte subsets in each individual sample in patient groups, based on CD14 and CD16 expression (left panels) or CD11b and HLA-DR expression (right panels).(J) Fractions of non-classical monocytes among total monocytes as in (E).(K) CD11b and HLA-DR expression on classical monocytes in each patient group (data pooled per group).(L) Percentage of HLA-DR^low^ classical monocytes among classical monocytes as in (E).(M) Percentage of B, CD4^+^ T, CD8^+^ T, and NK cells among total cells as in (E).Kruskal-Wallis test, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001; ns, non-significant.Figure S1Spectral Flow Analysis of Peripheral Blood Cells in a Learning Cohort of Controls and COVID-19 Patients, Related to [Figure 1](#fig1){ref-type="fig"} and [Table S2](#mmc1){ref-type="supplementary-material"}A. Representative example of data pooling of individual UMAP profiles obtained from 3 patients of the same group. Here, neutrophil subsets are identified based on CD10 and CD101 expression across cells from patients 1, 2 and 3, allowing the analysis of cell subset repartition within the group; B. Cell surface marker expression identifying cell populations on UMAP analysis generated by data pooling from all the tested samples; C. UMAP profile from pooled data on neutrophils in all patients or indicated group of patients; D-E. Percentage of CD10^High^ (D) or CD16^Low^ neutrophils (E) among total neutrophils in all individuals of indicated groups; F. UMAP profile from pooled data on monocytes in all patients or indicated group of patients; G-H. Percentage of CD14^+^ (G) or CD11b^High^ (H) monocytes among total monocytes in all individuals of indicated groups; Kruskal-Wallis test, ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ns, non-significant.

Patients with severe disease exhibited an expansion in the proportion of circulating neutrophils within the peripheral blood cell population ([Figure 1](#fig1){ref-type="fig"}E) that was associated with an increase in their absolute numbers ([Table S2](#mmc1){ref-type="supplementary-material"}), as already reported ([@bib30]). Focusing on neutrophil subsets, we noticed a slight increase in the fraction of CD10^Low^CD101^+^ neutrophils in patients with mild COVID-19 ([Figure 1](#fig1){ref-type="fig"}F), whereas the fraction of CD10^Low^CD101^−^ neutrophils was remarkably amplified in patients with severe disease, suggesting an accumulation of immature subsets of neutrophils ([@bib42]) in the peripheral blood of these patients ([Figures 1](#fig1){ref-type="fig"}G and [S1](#figs1){ref-type="fig"}C--S1E).

In patients with severe disease, the absolute numbers of circulating monocytes ([Table S2](#mmc1){ref-type="supplementary-material"}) and the proportion of total monocytes among peripheral blood leucocytes ([Figures 1](#fig1){ref-type="fig"}H and [S1](#figs1){ref-type="fig"}F) were similar to controls, but we noticed changes in monocyte subset repartition. The fraction of CD14^High^CD16^High^ intermediate monocytes was significantly greater in patients with mild COVID-19 (16.95% ± 6.75%) than in the control (5.84% ±1.02%) or severe (6.77% ± 1.10%) groups, whereas the non-classical CD14^Low^CD16^High^ monocyte fraction was lower in patients with severe COVID-19 (1.31% ± 0.35%) than in the mild (5.46% ± 1.57%) or control groups (6.68% ± 1.14%) ([Figures 1](#fig1){ref-type="fig"}I and 1J). Within the CD14^High^CD16^Low^ classical monocyte subset ([Figure S1](#figs1){ref-type="fig"}G), we detected higher frequencies of CD11b^High^ monocytes with increased disease severity ([Figure S1](#figs1){ref-type="fig"}H), whereas the intensity of HLA-DR expression was lower across the CD11b^+^ and CD11b^−^ monocyte populations of patients with severe COVID-19 ([Figures 1](#fig1){ref-type="fig"}K and 1L).

Changes in myeloid cell repartition observed in patients with severe disease were associated with lower frequencies of B cells compared with controls (p \< 0.001) and of CD4^+^ (p \< 0.001) and CD8^+^ T cells (p \< 0.01) relative to controls and patients with mild disease, whereas CD56^+^ natural killer (NK) cell frequencies remained comparable across all groups ([Figure 1](#fig1){ref-type="fig"}M).

Altogether, these data suggested that SARS-CoV-2-induced changes in the relative abundance of monocyte and neutrophil subsets within the peripheral blood cell population, with loss of non-classical CD14^Low^CD16^High^ monocytes, reduced the expression of HLA-DR on classical monocytes and a drop in CD101 and CD10 expression on neutrophils, characterizing severe cases.

Serial Single-Cell Analysis of Mild versus Severe Patient Blood Cells Identifies Dynamic Changes in Monocyte Subsets {#sec2.3}
--------------------------------------------------------------------------------------------------------------------

As a second step in our discovery process, we collected peripheral blood samples from three control patients with flu-like symptoms who tested negative for SARS-CoV-2 and three SARS2-CoV-2-positive patients, one outpatient with mild disease and two patients with severe disease admitted to the ICU ([Figures 2](#fig2){ref-type="fig"}A and 2B; [Table S3](#mmc1){ref-type="supplementary-material"}). Using the 10X Chromium droplet-based platform, these samples were subjected to single-cell RNA sequencing (scRNA-seq) immediately after collection and red blood cell lysis, without additional sorting or freezing, to preserve fragile cell populations, mainly neutrophils. Unsupervised clustering based on gene expression identified B and T cells as well as neutrophils, monocytes, erythroid cells, and platelets ([Figures 2](#fig2){ref-type="fig"}C, [S2](#figs2){ref-type="fig"} A, and S2B). Samples analyzed by scRNA-seq were analyzed simultaneously by spectral flow cytometry for comparison ([Figure 2](#fig2){ref-type="fig"}D). UMAP analysis of spectral flow cytometry data suggested lower proportions of CD4^+^ and CD8^+^ T cells, whereas the neutrophil fraction was greater in patients with severe disease compared with controls and with the unique patient with mild disease ([Figures 2](#fig2){ref-type="fig"}E and [S2](#figs2){ref-type="fig"}C). The three SARS2-CoV-2-infected patients were sampled again 10 days later to monitor progression of the immune response in relation to clinical status ([Figures 2](#fig2){ref-type="fig"}A--2E).Figure 2scRNA-Seq of Peripheral Blood Cells in SARS-CoV-Negative and SARS-CoV-Positive Patients(A) Two blood samples were collected 10 days apart from 3 COVID-19 patients. Blood was also collected once from 3 outpatient controls whose SARS-CoV-2 RT-PCR was negative. Individual cell mRNAs were sequenced using Chromium 10X technology.(B) Timeline of sample collection in the three patients (further details in [Table S4](#mmc2){ref-type="supplementary-material"}).(C) UMAP analysis of the 9 sequenced samples showing repartition of the indicated cell populations. Patient samples were analyzed individually at days 0 and 10; for control patient individual analyses, see [Figure S2](#figs2){ref-type="fig"}.(D) Spectral flow cytometry analysis of surface marker expression performed on the same samples.(E) UMAP analysis of cell populations detected by spectral flow cytometry data in each patient at day 0 and at day 10 and in controls (for individual analyses, see [Figure S2](#figs2){ref-type="fig"}).Figure S2Single-Cell Analysis of Peripheral Blood Cells, Related to [Figure 2](#fig2){ref-type="fig"} and [Tables S3](#mmc1){ref-type="supplementary-material"} and [S4](#figs4){ref-type="fig"}A. Heatmap of gene expression used to identify cell populations in scRNaseq experiments; B-C. Individual UMAP analysis of each control sample analyzed by scRNaseq (B) and spectral flow cytometry (C).

UMAP visualization of monocytes analyzed by scRNA-seq identified three clusters ([Figure 3](#fig3){ref-type="fig"} A) that may correspond to well-defined monocyte subsets ([@bib25]). Cells of cluster 1 expressed *CD14*, *ITGAM* (encoding CD11b), and *KLF4* while poorly expressing *FCGR3A* (encoding CD16), suggesting classical monocytes. Cells of cluster 3, which expressed high levels of *FCGR3A* and low levels of *CD14*, may correspond to non-classical monocytes, and cluster 2, in which cells expressed *CD14* and *FCGR3A*, evoked intermediate monocytes ([Figure 3](#fig3){ref-type="fig"}A). Differentially expressed genes (DEGs) and pathway analyses delineated a type I interferon signature in monocytes of patients with mild COVID-19 ([Figures 3](#fig3){ref-type="fig"}B, [S3](#figs3){ref-type="fig"} A, and S3B; [Table S4](#mmc2){ref-type="supplementary-material"}). This signature was less pronounced in the two severe COVID-19 samples, contrasting with the elevated expression of genes involved in production of reactive oxygen species (ROS) and nitric oxygen species (NOS) ([Figures S3](#figs3){ref-type="fig"}A and S3B).Figure 3Single-Cell Analysis of Monocytes by scRNA-Seq, Spectral Flow Cytometry, and Mass Cytometry(A) UMAP profile of monocytes in the samples described in [Figure 2](#fig2){ref-type="fig"}A and violin plots of gene expression in three statistically defined clusters.(B) Heatmap of differentially expressed genes (DEGs; logFC ± 0.25; false discovery rate (FDR) \< 0.05) in total monocytes; columns labeled "0" identify DEGs generated by comparing each patient sample at day 0 with the pool of the three controls and the two other patient samples at day 0. Columns labeled "10" identify the expression of these genes in each patient sample at day 10 compared with day 0. Genes are shown in [Table S4](#mmc2){ref-type="supplementary-material"}.(C--E) Spectral flow analysis of pooled controls and each individual patient sample at day 0 and day 10 of monocyte subset partition in samples analyzed by scRNA-seq (C), CD11b and CD141 expression among classical monocytes (D), and CD169 and HLA-DR expression among classical monocytes (E).(F--I) Mass cytometry analysis of monocyte subsets in 4 patients within each group (pooled data) (F), non-classical monocyte fraction among total monocytes in each individual sample within the 3 groups (G), p65/NF-κB expression in HLA-DR^low^ classical monocyte subset as in (F) (H), and fraction of p65/NF-κB^high^HLA-DR^low^ classical monocytes among classical monocytes as in (G) (I). Kruskal-Wallis test, ^∗^p \< 0.05.Figure S3Monocyte Analysis by scRNA-Seq, Spectral Flow Cytometry, and Mass Cytometry, Related to [Figure 3](#fig3){ref-type="fig"} and [Tables S3](#mmc1){ref-type="supplementary-material"}, [S4](#figs4){ref-type="fig"}, and [S5](#figs5){ref-type="fig"}A. Pathway analysis generated by comparing DEGs in monocytes of each SARS-CoV-2 positive patient to the same population in the three control patients considered together using IPA software (mild patient in blue, severe \#1 in red, severe \# 2 in orange); B. The same DEGs were used to perform a gene ontology network analysis using clueGO software, considering the two severe patients together; C. Combined (left panel) and individual (right panel) mass cytometry analysis of p65/NF-κB expression in circulating CD34^+^ cells in each group. Kruskal-Wallis test, non-significant.

A non-supervised UMAP analysis of the data collected by spectral flow cytometry of the same samples detected variations in monocyte subset repartition among patients; compared with controls and the patient with mild disease, patient 1 with severe disease showed a lower fraction of CD14^Low^CD16^High^ non-classical monocytes at day 0, whereas the other patient with severe disease showed a high level of this monocyte fraction ([Figure 3](#fig3){ref-type="fig"}C). Additionally, the two patients with severe disease showed markedly higher levels of classical CD14^High^CD16^Low^ monocytes, expressing more CD141 (*THBD*) at their surface ([Figure 3](#fig3){ref-type="fig"}D), in accordance with the scRNA-seq analysis ([Table S4](#mmc2){ref-type="supplementary-material"}).

In the patient with mild disease, one of the most highly expressed genes in classical monocytes was the interferon-stimulated gene ([@bib49]) *SIGLEC-1*, consistent with the high level of expression of CD169, the corresponding protein, at the surface of classical monocytes at day 0 ([Figure 3](#fig3){ref-type="fig"}E). Ten days later, *SIGLEC-1* gene expression was downregulated, and CD169 expression was undetectable at the surface of HLA-DR^High^ classical monocytes ([Figures 3](#fig3){ref-type="fig"}B and 3E). The two patients with severe disease exhibited low expression of HLA-DR protein on monocyte surfaces at day 0, without significant change at day 10 ([Figure 3](#fig3){ref-type="fig"}E).

Validating these discovery experiments, we performed mass cytometry analysis of an independent cohort of 12 patients (four in each group; control, mild, and severe) ([Table S5](#mmc1){ref-type="supplementary-material"}), which showed a lower fraction of CD14^Low^CD16^High^ non-classical monocytes in patients with severe compared with mild disease ([Figures 3](#fig3){ref-type="fig"}F and 3G). In accordance with pathway analysis of scRNA-seq data highlighting nuclear factor κB (NF-κB) activation as a prominent feature in monocytes of patients with severe disease ([Figures 3](#fig3){ref-type="fig"}B and [S3](#figs3){ref-type="fig"}B), we observed significantly higher levels of the phosphorylated transcription factor RelA/p65 (P-p65), a critical effector of the canonical NF-κB pathway, in HLA-DR^Low^CD14^High^ classical monocytes from patients with severe disease compared with controls ([Figures 3](#fig3){ref-type="fig"}H and 3I). We also measured P-p65 expression in circulating CD34^+^ cells, identifying increased expression in severe disease ([Figure S3](#figs3){ref-type="fig"}C).

Serial Single-Cell Analysis of Blood Cells from Patients with Mild versus Severe Disease Identifies Changes in Neutrophil Subsets {#sec2.4}
---------------------------------------------------------------------------------------------------------------------------------

UMAP analysis of neutrophils identified two clusters ([Figure 4](#fig4){ref-type="fig"} A). We observed an increase of cluster 2 cells in patients with severe COVID-19 ([Figure 4](#fig4){ref-type="fig"}B). Cluster 1 expressed the *IL1R2* gene, whereas cluster 2 also expressed high levels of *S100A8* and *S100A9*, *CXCR4*, *SELL*, and *SPI1* ([Figures 4](#fig4){ref-type="fig"}C and [S4](#figs4){ref-type="fig"} A). DEGs and pathway analyses in neutrophils of patients with mild disease informed about a type I interferon response at day 0 that was lost by day 10 ([Figures 4](#fig4){ref-type="fig"}D, [S4](#figs4){ref-type="fig"}B, and S4C). This signature was absent in controls and also in the two samples collected from patients with severe disease at later time points ([Figure 4](#fig4){ref-type="fig"}D), demonstrating high expression of genes involved in production of ROS, the inducible NOS pathway, IL-1 signaling, and NF-κB activation pathways ([Figures S4](#figs4){ref-type="fig"}B and S4C).Figure 4Single-Cell Analysis of Neutrophils by scRNA-Seq, Spectral Flow Cytometry, and Mass Cytometry(A) UMAP profile of neutrophils in the 9 samples analyzed as described in [Figure 2](#fig2){ref-type="fig"}A.(B) UMAP profile of neutrophils within the 3 controls and the mild and the two severe cases with the cluster gates overlaid.(C) Violin plots of expression of the indicated genes in two statistically defined neutrophil clusters.(D) Heatmap of DEGs in total neutrophils generated as described in [Figure 3](#fig3){ref-type="fig"}B.(E and F) Spectral flow analysis of neutrophil subsets in pooled controls and each individual patient sample at day 0 and day 10, based on CD10 and CD101 expression (E) and CXCR4 and CD11b expression among CD10^Low^CD101^−^ neutrophils (F) in the indicated samples (pooled controls).(G and H) Mass cytometry analysis of neutrophil subsets in 4 patients within each group (pooled data) as in [Figures 3](#fig3){ref-type="fig"}F--3I, based on CD10 and CD101 expression (G) and the fraction of CD10^Low^CD101^--^ neutrophils among total neutrophils in each sample within the 3 groups (H). Kruskal-Wallis test, ^∗^p \< 0.05.Figure S4Neutrophil Analysis by scRNA-Seq, Spectral Flow Cytometry, and Mass Cytometry, Related to [Figure 4](#fig4){ref-type="fig"} and [Tables S3](#mmc1){ref-type="supplementary-material"}, [S4](#figs4){ref-type="fig"}, and [S5](#figs5){ref-type="fig"}A. Heatmap of the top 20 DEGs defining two neutrophil clusters. B. Pathway analysis generated by comparing DEGs in neutrophils of each SARS-CoV-2 patient to the same population in the three control patients considered together using IPA software (mild patient in blue, severe \#1 in red, severe \# 2 in orange); C. The same DEGs identified in neutrophils were used to perform a gene ontology network analysis using clueGO software, considering the two severe patients together.

Analysis of the data collected by spectral flow cytometry of the same samples distinguished CD10^+^CD101^+^ mature neutrophils from CD10^Low^CD101^−^ immature neutrophils. At day 0, the two patients with severe disease had more circulating CD10^Low^CD101^−^ immature neutrophils compared with controls or the patient with mild disease ([Figure 4](#fig4){ref-type="fig"}E). Neutrophils from patient 1 with severe disease had increased expression of CD101 on their surfaces at day 10, whereas neutrophils from patient 2 with severe disease retained their immature phenotype at day 10. Focusing on expression of a pre-neutrophil hallmark, CXCR4, on the surface of CD10^Low^CD101^−^ immature neutrophils ([@bib42]), we observed an increase in the proportion of neutrophils with a CD10^Low^CD101^−^CXCR4^+^ phenotype, which, presumably, are pre-neutrophils ([Figure 4](#fig4){ref-type="fig"}F). Mass cytometry analysis of an independent cohort of 12 patients (four controls, four patients with mild COVID-19, and four patients with severe COVID-19; [Table S5](#mmc1){ref-type="supplementary-material"}) again suggested a higher fraction of CD10^Low^CD101^−^ immature neutrophils in patients with severe disease compared with control patients ([Figures 4](#fig4){ref-type="fig"}G and 4H).

Altogether, the results of these exploratory scRNA-seq experiments identified a transient type I interferon response in cells of a patient with mild disease and the presence of phenotypically immature subsets of monocytes and neutrophils in two patients with severe disease, which was further confirmed by mass cytometry.

Calprotectin Plasma Levels Distinguish Patients with Mild from Patients with Severe COVID-19 {#sec2.5}
--------------------------------------------------------------------------------------------

S100A8 and S100A9 alarmins, representing ∼45% of the cytoplasmic proteins in neutrophils, are released under inflammatory conditions and form a stable heterodimer known as "calprotectin" ([@bib63]). In accordance with preliminary results generated by scRNA-seq ([Figure S4](#figs4){ref-type="fig"}A), qRT-PCR analysis detected higher expression of the *S100A8* and *S100A9* genes in peripheral blood nucleated cells of patients with severe COVID-19 (n = 8) compared with controls (n = 8) and patients with mild disease (n = 16) ([Figure S5](#figs5){ref-type="fig"} A; [Table S5](#mmc1){ref-type="supplementary-material"}). This led us to measure the plasma level of calprotectin, together with type I interferon (IFNα) and 40 other cytokines and chemokines, in samples from a cohort of 84 patients ([Table S6](#mmc1){ref-type="supplementary-material"}). As seen in [Figure 5](#fig5){ref-type="fig"} A, patients with mild disease showed significantly less CXCL8 ([Figures 5](#fig5){ref-type="fig"}C and [S5](#figs5){ref-type="fig"}B) and significantly more type I IFNα ([Figures 5](#fig5){ref-type="fig"}A and 5C) compared with controls. Patients with severe disease exhibited dramatically higher calprotectin levels compared with patients with mild COVID-19 or controls, without a further increase in IFNα plasma levels above mild disease levels ([Figures 5](#fig5){ref-type="fig"}B, 5C, and [S5](#figs5){ref-type="fig"}C). Calprotectin was the most significantly increased circulating biomarker in patients with severe disease, accompanied by a rise in 23 other tested chemokines and cytokines, including CXCL-8, CXCL-12, and IL-6 ([Figures 5](#fig5){ref-type="fig"}B, 5C, and [S5](#figs5){ref-type="fig"}B).Figure S5Calprotectin Is the Most Abundant Immune Mediator/Immune Protein Detected in the Plasma of Patients with Severe COVID-19, Related to [Figure 5](#fig5){ref-type="fig"} and [Tables S5](#mmc1){ref-type="supplementary-material"} and [S6](#figs6){ref-type="fig"}A. RT-qPCR analysis of *S100A8* and *S100A9* gene expression in the three groups of patients, using *HPRT* as a control gene; B. Heatmap of cytokines, chemokines, IFNα2a and calprotectin plasma levels in 37 COVID-19 patients compared to 40 controls. SARS-CoV-2-positive patients included 14 mild and 23 severe patients. Associated bacterial infection at sample collection is indicated in purple. The heatmap shows z score-normalized concentrations, each column represents one patient and each row one protein; the color gradient from blue to red indicates increasing concentrations. Rows and columns are clustered using correlation distance and average linkage; C. Volcano-plot representation of cytokine levels in severe SARS-CoV-2 patients with (n = 11) or without (n = 14) bacterial infection at the time of sample collection; D. Spearman correlation between calprotectin concentration and age showing control patients in green, mild in orange and severe in red; E. Spearman correlation between IL-6 and calprotectin concentrations (color code as in D).Figure 5Calprotectin Is the Most Abundant Immune Mediator Detected in the Plasma of Patients with Severe COVID-19Shown are plasma levels of calprotectin (S100A8/S100A9), interferon alpha (IFNα2a), and 40 cytokines and chemokines in blood samples collected from 84 patients (controls, 40; mild disease, 18; moderate or severe disease, 25).(A) Volcano plot of cytokine levels in patients with mild COVID-19 compared with controls; IFNα2a is shown in orange.(B) Volcano plot of cytokine levels in patients with severe COVID-19 compared with control patients; IFNα2a is shown in orange. Calprotectin, CXCL11, CXCL13, and CX3CL1, shown in red, are most significantly associated with the severe forms.(C) Circulating levels of CXCL8, IFNα2a, calprotectin, and IL-6 in individual samples in each group.(D) Effect of comorbidities ([Table S6](#mmc1){ref-type="supplementary-material"}) on calprotectin plasma levels in each group.(E) Volcano plot of cytokine levels in patients with severe disease with and without comorbidities.(F) Effect of bacterial infection on calprotectin plasma levels in each group.(G--I) Spearman correlations between calprotectin plasma levels and neutrophil count (G), fibrinogen (H), and D dimers (I).(J--L) Spearman correlations between IL-6 plasma levels and neutrophil count (J), fibrinogen (K), and D dimers (L).Wilcoxon rank-sum test, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001.

Age and comorbidities (including obesity, diabetes mellitus, cardiovascular and respiratory diseases, and cancer) are predictors of severe COVID-19 disease ([@bib46]). We found that plasma calprotectin levels were significantly higher in control patients with comorbidities as well as in mild or severe COVID-19 patients with comorbidities ([Figure 5](#fig5){ref-type="fig"}D). Nevertheless, the increase in calprotectin in patients with severe COVID-19 far exceeds correlations associated with comorbidities. None of the other measured circulating proteins were significantly higher in patients with comorbidities ([Figure 5](#fig5){ref-type="fig"}E). Bacterial infections can occur in patients with severe COVID-19 ([@bib12]; [@bib38]) and were present in some of our patients with severe disease but did not significantly modify the profile of released proteins ([Figures S5](#figs5){ref-type="fig"}B and S5C), including calprotectin ([Figure 5](#fig5){ref-type="fig"}F). No correlation between calprotectin and age was observed in any group of patients ([Figure S5](#figs5){ref-type="fig"}D). Calprotectin concentration correlated with neutrophil counts ([Figure 5](#fig5){ref-type="fig"}G), fibrinogen plasma levels ([Figure 5](#fig5){ref-type="fig"}H), and D dimers ([Figure 5](#fig5){ref-type="fig"}I), the latter being fibrin degradation products reflecting a hypercoagulability state. When modeling calprotectin plasma levels using multivariable linear regression to take into account potential confounding factors (age, sex, and comorbidities) and the correlation with neutrophil count, fibrinogen, and D dimers, these associations were still statistically significant (neutrophils, p = 1.154e−04; fibrinogen, p = 5.688e−05; D dimers, p = 2.099e−03). We also uncovered a weak correlation between IL-6 plasma concentration and levels of calprotectin ([Figure S5](#figs5){ref-type="fig"}E), blood neutrophil count ([Figure 5](#fig5){ref-type="fig"}J), fibrinogen ([Figure 5](#fig5){ref-type="fig"}K), and D dimers ([Figure 5](#fig5){ref-type="fig"}L), which disappeared after adjusted multilinear regression. Finally, a logistic regression including age, sex, and comorbidities together with biological parameters identified plasma levels of calprotectin, CX3CL1, CXCL11, and CXCL13 as the parameters that best discriminate controls/patients with mild COVID-19 from patients with severe disease.

These results indicate that high plasma levels of calprotectin are seen in patients with severe COVID-19 but not in those with mild disease. Importantly, this increase is independent of confounding factors for prognosis, such as advanced age, comorbidities, or concurrent bacterial infection, which have only minor effects on plasma calprotectin levels.

Spectral Flow Analyses Validate a Contrasted Innate Immune Cell Signature in Mild versus Severe COVID-19 {#sec2.6}
--------------------------------------------------------------------------------------------------------

The hypothesis from the scRNA-seq-based identification of CD37, CD63 (LAMP3), CD169 (SIGLEC-1), and CD184 (CXCR4) biomarkers of blood cell subsets, whose relative proportions differ in patients with mild and severe COVID-19, prompted us to add antibodies targeting these proteins to the spectral flow cytometry panel. We applied this new panel to samples from an independent validation cohort of 90 patients. This cohort included 48 control patients and 42 COVID-19-positive patients, of whom 16 had mild disease and 26 had severe disease ([Figure 6](#fig6){ref-type="fig"} A; [Table S6](#mmc1){ref-type="supplementary-material"}). Non-supervised analysis and UMAP visualization identified the main cell populations in the three categories of patients combined ([Figures S6](#figs6){ref-type="fig"} A and S6B). Analyzing patients individually confirmed the significant decrease in B cell, CD4^+^ T cell, and CD8^+^ T cell fractions in severe patients compared with the control and mild disease groups ([Figure 6](#fig6){ref-type="fig"}B), which may be a consequence of the increased neutrophil fraction ([Figure 6](#fig6){ref-type="fig"}C) and absolute numbers ([Table S6](#mmc1){ref-type="supplementary-material"}). More specifically, within neutrophils, we observed a shift in CD10^Low^CD101^−^ neutrophils ([Figures 6](#fig6){ref-type="fig"}D and 6E) and the subset of CD10^Low^CD101^−^ neutrophils that express CXCR4 (CD10^Low^CD101^−^CXCR4^+^ cells) ([Figure 6](#fig6){ref-type="fig"}F) we observed previously in patients with severe disease. Finally, the fraction of CD10^Low^CD16^Low^ neutrophils was also higher in patients with severe disease ([Figure S6](#figs6){ref-type="fig"}C), suggesting accumulation of immature neutrophils in the blood of patients with severe COVID-19.Figure 6Validation of the Severe COVID-19 Innate Immune Signature(A) Spectral flow pipeline.(B) Fraction of B cells, CD4^+^ T cells, CD8^+^ T cells, and NK cells among total cells in individual samples (circles) in each group.(C) Fraction of neutrophils in individual samples in each group.(D) Neutrophil subsets identified by CD101 and CD10 expression in each group (pooled data).(E) Fraction of CD10^Low^CD101^−^ neutrophils among total neutrophils in individual samples within each group.(F) Fraction of CXCR4^+^ neutrophils among CD10^Low^CD101^--^ neutrophils as in (E).(G) Spearman correlation of time spent in the ICU and non-classical monocyte fraction among total monocytes. Patients with a bacterial infection are shown as red dots. Mean time spent in the ICU was 5.46 days for patients with a low (≤5%) and 8.83 days in those with a high (\>5%) CD14^low^CD16^High^ monocyte fraction.(H) Fraction of classical monocytes among white blood cells in each individual sample in each group.(I) Fraction of non-classical monocytes among total monocytes as in (H).(J) Monocyte subset partition in each group (pooled data), with the severe group split in two groups based on mean time spent in the ICU. Top panels: monocyte subsets identified by CD14 and CD16 expression. Bottom panels: HLA-DR and CD169 or CD11b and CD141 expression in the classical monocyte subset.(K) Fraction of monocytes expressing CD169 among classical monocytes as in (H).(L) Fraction of monocytes expressing CD141 among classical monocytes as in (H).Kruskal-Wallis test, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.Figure S6Validation of the Innate Immune Signature of Severe COVID-19, Related to [Figure 6](#fig6){ref-type="fig"} and [Table S6](#mmc1){ref-type="supplementary-material"}A-B Non-supervised UMAP representation generated by pooling data from all the patient samples; cell identification (A) surface marker expression (B); C. Bar plots representing the percentage of CD10^Low^CD16^Low^ neutrophils among all neutrophils in individual patients from each group in the validation cohort (n = 90). D. Spearman correlation between CD169 (*SIGLEC-1*) mean fluorescence intensity (MFI) and days spent by severe patients in ICU. E. Spearman correlation between CD169 (*SIGLEC-1*) mean fluorescence intensity (MFI) and plasma IFNα concentration; yellow, mild COVID-19 patients; red, severe COVID-19 patients. F.G. Bar plots representing the percentage of HLA-DR^Low^ classical monocytes, B cells, CD4^+^ and CD8^+^ T cells and NK cells (F) and neutrophils among CD45^+^ cells, CD10^Low^CD101^-^ neutrophils among all neutrophils and CD10^Low^CXCR4^+^ neutrophils among CD10^Low^CD101^-^ neutrophils (G) in individual patients from each group in the validation cohort (n = 90). Kruskal-Wallis test, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001; ns, non-significant.

scRNA-seq analyses of monocyte subsets indicated differential changes in the distribution of non-classical CD14^Low^CD16^High^ monocyte fractions in the two patients with severe disease ([Figure 3](#fig3){ref-type="fig"}C). Because samples were collected from patients at various time points after admission to the ICU, we wanted to find out whether the duration of ICU stay affects monocyte subset distribution. In the 26 patients of this cohort with severe disease ([Table S6](#mmc1){ref-type="supplementary-material"}), we observed a significant correlation between the time spent in the ICU and the fraction of the non-classical monocyte subset, irrespective of the presence or absence of concurrent bacterial infection ([Figure 6](#fig6){ref-type="fig"}G). The mean time spent in the ICU was 5.46 days for patients with fewer than 5% non-classical monocytes compared with 8.83 days for those with 5% and more non-classical monocytes ([Figures 6](#fig6){ref-type="fig"}H and 6I).

Then we examined other monocyte subsets. In the majority of patients with mild disease, we observed a fraction of classical monocytes that express CD169, which was decreased in patients with severe disease ([Figures 6](#fig6){ref-type="fig"}J, 6K, and [S6](#figs6){ref-type="fig"}D). CD169 expression correlated with IFNα plasma levels ([Figure S6](#figs6){ref-type="fig"}E). Independent of the time spent in the ICU, patients with severe disease also showed a larger fraction of classical monocytes expressing high levels of CD141 compared with controls ([Figures 6](#fig6){ref-type="fig"}J and 6L) and of monocytes expressing low levels of HLA-DR compared with controls and patients with mild disease ([Figure S6](#figs6){ref-type="fig"}F). Finally, the time spent in the ICU did not significantly affect repartition of lymphocyte populations or neutrophil subsets ([Figures S6](#figs6){ref-type="fig"}F and S6G).

Thus, patients with severe COVID-19 exhibited a transient decrease in non-classical monocyte frequencies, a stable decrease in HLA-DR^Low^CD141^+^ classical monocytes, and a major increase in CD10^Low^CD101^−^CXCR4^+/−^ immature neutrophils.

A High Calprotectin Level and Loss of Non-classical Monocytes Correlate with COVID-19 Severity {#sec2.7}
----------------------------------------------------------------------------------------------

We next investigated whether changes in circulating myeloid cell phenotypes could be used to discriminate patients who develop severe COVID-19. Within our previous cohort, we separated patients with mild (n = 12) from patients with moderate (n = 6) and severe (n = 27) disease using clinical criteria. Patients classified as having "moderate" disease demonstrated intermediate changes between those of outpatients with mild disease and patients with severe disease in the ICU ([Figure S7](#figs7){ref-type="fig"} A). The fraction of CD10^Low^CD101^−^ neutrophils in patients with moderate disease was intermediate but not significantly different from any group ([Figure 7](#fig7){ref-type="fig"} A). However, the amount of calprotectin measured in patients with moderate COVID-19 was significantly higher than in outpatients with mild disease but still significantly lower than in patients with severe COVID-19 ([Figure 7](#fig7){ref-type="fig"}B). In comparison, IFNα levels were not significantly different between patients with moderate and mild disease or patients with severe disease ([Figure S7](#figs7){ref-type="fig"}B). The difference in non-classical monocyte fraction was significant between patients with mild and moderate disease, dropping to levels comparable with patients with severe disease ([Figure 7](#fig7){ref-type="fig"}C).Figure S7Changes in Innate Immune Cell Phenotype Are Detected in Patients with Moderate COVID-19, Related to [Figure 7](#fig7){ref-type="fig"} and [Tables S6](#mmc1){ref-type="supplementary-material"} and [S7](#figs7){ref-type="fig"}A. Bar plots representing the percentage of B cells, CD4^+^ T cells, CD8^+^ T cells, NK cells, total monocytes, CD169^+^, HLA-DR^Low^ and CD141^+^ classical monocyte subsets, total neutrophils among CD45^+^ cells, and CD10^Low^CD101^-^ and CD10^Low^CD16^Low^ neutrophil subset among all neutrophils in individual patients from each group, with the moderate category (6 patients) highlighted. B. Plasma concentration of IFNα in moderate COVID-19 patients compared to the three other groups. C. ROC analysis showing performance of a diagnostic test using percentage of non-classical monocytes among total monocytes to distinguish controls and mild COVID patients from moderate and severe COVID patients; D. Monocyte subset analysis in the peripheral blood of 2 severe patients, before (left panels) and after (right panels) treatment with the indicated anti-IL-6 antibodies; E. Percentage of HLA-DR^low^ classical monocytes among classical monocytes in a cohort of 22 patients and 17 controls grouped into 4 clinical categories; F. Correlation between the percentage of HLA-DR^low^ classical monocytes and non-classical monocytes; G. Percentage of CD16^low^ neutrophils among neutrophils in control and COVID-19 patients of the learning cohort described in [Figure 7](#fig7){ref-type="fig"}. H. ROC curves evaluating the discriminating significance of calprotectin plasma level (yellow), nonclassical monocyte fraction (red), CD16^low^ circulating neutrophils (blue) and IFNα2a plasma level (white) between controls/mild patients and moderate/severe patients. AUC, Area Under the Curve; Mann Whitney test; I. Heatmap of blood and bronchoalveolar lavage fluid scRNaseq cells integrated defining the 5 regions of cell populations; J. Pathway analysis (Cytoscape and ClueGo) of DEGs expressed at a higher level in bronchoalveolar monocytes/macrophages from mild versus severe patients. K. UMAP analysis of neutrophils with *S100A8* (left panel) and *S100A9* (right panel) gene expression level projection (low expression = gray dots; high expression = dark blue dots). Kruskal-Wallis test, ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001.Figure 7Low-Dimensional Flow Analysis of Non-classical Monocyte Subsets in COVID-19(A) Fraction of CD10^Lcow^CD101^−^ neutrophils among total neutrophils in individual samples within each group, separating moderate and severe COVID-19.(B) Calprotectin plasma levels in patients with moderate disease (orange dots) compared with patients of the three other groups.(C) Fraction of non-classical monocytes among total monocytes in patients with moderate disease (green bar plot) compared with patients of the three other three groups.(D and E) Fraction of non-classical monocytes among total monocytes in a learning cohort of 98 patients (controls, n = 56; mild, n = 16; moderate, n = 10; severe, n = 16) (D) and a validation cohort of 24 patients (controls, n = 10; mild n = 3; moderate, n = 4; severe, n = 7) (E). Mann-Whitney test, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(F--M) Integration of scRNA-seq data from blood and lung (BALF) cells of COVID-19 patients. Blood samples are described in [Tables S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc2){ref-type="supplementary-material"}. Lung data are from [@bib37] (controls, n = 3; mild, n = 3; severe, n = 6).(F) UMAP analysis of integrated scRNA-seq from blood and lung samples.(G) UMAP analysis of blood and lung samples in each patient category.(H) UMAP analysis of integrated scRNA-seq data of monocytes/macrophages from blood and lungs.(I) UMAP analysis of blood and lung monocytes/macrophages in each patient group.(J) Violin plot of gene expression in lung monocytes/macrophages of control patients and patients with mild and severe disease.(K) UMAP analysis of integrated scRNA-seq data of neutrophils from blood and lung samples.(L) UMAP analysis of blood and lung neutrophils in each patient group.(M) Violin plot of gene expression in lung neutrophils of control patients and patients with mild and severe COVID-19.(N) UMAP analysis of neutrophils with *CXCR4* gene expression level projection (low expression, gray dots; high expression, dark blue dots).

Thus, we hypothesized that the decreased non-classical monocyte fraction could be used as a fast and simple diagnostic test to distinguish moderate from mild COVID-19, especially in patients in whom clinical symptoms may be substantially overlapping. This would facilitate rapid and accurate identification of patients currently classified as having mild disease at the cusp of potentially progressing to more severe disease. We therefore employed a low-dimensional flow cytometry approach that measures the fraction of classical (CD14^High^CD16^Low^), intermediate (CD14^High^CD16^High^), and non-classical (CD14^Low^CD16^High^) monocyte subsets among total peripheral blood monocytes and applied it initially to a learning cohort of 98 patients, consisting of 16 patients with mild disease, 10 with moderate disease, and 16 with severe COVID-19, along with 56 controls ([Table S7](#mmc1){ref-type="supplementary-material"}). All hospitalized patients were sampled within 10 days of admission to limit the potential effect of time spent in the ICU (see [Figure 6](#fig6){ref-type="fig"}G); the mean time spent in the ICU was 5.5 days at the point of sampling. The cohort also included 56 controls. Patients with mild disease showed a fraction of non-classical monocytes similar to that observed in controls. In contrast, moderate patients showed lower levels of non-classical monocytes, as observed in patients with severe disease ([Figure 7](#fig7){ref-type="fig"}D). To measure the global performance of this test, we used a receiver operating characteristic (ROC) curve ([@bib27]). The point of the ROC curve corresponding to the best sensitivity/specificity compromise indicated that a non-classical monocyte fraction below 4% separated patients with moderate or severe COVID-19 from those with mild or no disease with 76.9% sensitivity (95% bootstrap confidence interval \[BCI\] \[61.5%, 92.3%\]) and 89% specificity (95% BCI \[80.6%, 95.8%\]) ([Figure S7](#figs7){ref-type="fig"}C).

We then applied these analyses to blood samples from an independent validation cohort of 24 hospitalized patients from a different clinical center (10 controls, 3 patients with mild disease, 4 with moderate disease, and 7 with severe COVID-19) ([Table S7](#mmc1){ref-type="supplementary-material"}). A non-classical monocyte fraction below 4% of total circulating monocytes, as defined in the learning cohort, also segregated those with mild disease from those with moderate and severe disease with high sensitivity (81.8%, 95% BCI \[72.7%, 100%\]) and specificity (92.3%, 95% BCI \[83.3%, 100%\]) ([Figure 7](#fig7){ref-type="fig"}E). These results confirmed the specificity and sensitivity of our assay to discriminate patients with different COVID-19 severity.

Further confirming these observations, serial sampling of two patients with severe disease who responded to anti-IL-6R antibodies documented that their clinical recovery was associated with reappearance of non-classical monocytes in the blood ([Figure S7](#figs7){ref-type="fig"}D). One patient who was initially referred with limited symptoms (atypical thoracic pain) and was SARS-Cov-2 PCR negative unexpectedly exhibited a low fraction of non-classical monocytes (3.4%) accompanied by 10% HLA-DR^Low^ classical monocytes. The following day, pulmonary symptoms appeared and the patient was hospitalized, requiring oxygen therapy, and a lung CT scan revealed characteristic COVID-19-associated injury. Such cases suggest that loss of the non-classical monocyte fraction could be a strong indicator of existing or impending severe COVID-19.

Additional informative parameters could be added to this flow assay to increase its specificity to identify transition to severe COVID-19, including decreased expression of HLA-DR on the surface of classical monocytes ([Figure S7](#figs7){ref-type="fig"}E), which is associated with a decrease in the non-classical monocyte fraction below 4% ([Figure S7](#figs7){ref-type="fig"}F), and an increase in the fraction of CD16^Low^ neutrophils ([Figure S7](#figs7){ref-type="fig"}G). Comparison of ROC curves indicated that calprotectin plasma level and monocyte or neutrophil subset analyses distinguished mild COVID-19 in outpatients from moderate or severe disease in hospitalized patients whereas IFNα2a plasma levels did not ([Figure S7](#figs7){ref-type="fig"}H).

Together with calprotectin plasma levels, flow identification of a decrease in the non-classical monocyte fraction below 4% of total monocytes could provide improved resolution for clinical observations when categorizing patients at the border of mild and moderate/severe COVID-19. This would potentially identify individuals at greatest risk of rapid decline and highlight the need for pro-active management/intervention and intensive monitoring. This assay could be reinforced by analysis of HLA-DR^Low^ classical monocyte and CD16^Low^ neutrophil fractions.

Integration of Lung and Blood scRNA-Seq Reveals Abnormal Myeloid Cell Populations Discriminating Severe and Mild COVID-19 {#sec2.8}
-------------------------------------------------------------------------------------------------------------------------

The lungs are major organs affected in patients with severe COVID-19. To better understand how the distinctive cell signatures found in the blood of patients with severe COVID-19 affect immune cell compartments in the lungs, particularly the presence of immature neutrophils and HLA-DR^Low^ monocytes, we integrated our dataset using the Seurat V3 pipeline ([@bib53]) with the published scRNA-seq dataset of cells from 12 bronchoalveolar lavage fluid samples (BALFs) of controls (n = 3) and patients with mild (n = 3) and severe (n = 6) COVID-19 ([@bib37]; Database: [GSE145926](ncbi-geo:GSE145926){#intref0010}). This analysis provided an unbiased global map of immune cells in the blood and BALF of controls and patients with mild and severe COVID-19. Using dimensional reduction, we identified 5 regions based on DEGs across pooled data from all samples ([Figures 7](#fig7){ref-type="fig"}F and [S7](#figs7){ref-type="fig"}I), including T cells (characterized by expression the *NKG7*, *CD8A*, *CST7*, *GZMB*, and *GZMA* genes), B cells (*IGLV3-19*, *IGHV4-34*, *IGHG1*, *IGHA1*, and *JCHAIN*), neutrophils (*G0S2*, *RSAD2*, *IL1R2*, and *IL1RN*), alveolar macrophages (*APOE*, *MSR1*, *MARCO*, and *FBP1*), and monocytes/macrophages (*FN1*, *CXCL10*, *CD68*, and *NUPR1*). Validating this approach, the alveolar macrophage region was mainly present in BALF of control patients but decreased dramatically in patients with mild and severe COVID-19,and only one cell from our blood scRNA-seq matched in this region ([Figures 7](#fig7){ref-type="fig"}F and 7G). We also observed changes in the monocyte/macrophage region of BALF from patients with mild or severe disease versus controls and dramatic neutrophil accumulation in patients with severe disease ([Figure 7](#fig7){ref-type="fig"}G).

Monocytes/macrophages were increased in BALF of the mild compared with the control and severe groups ([Figures 7](#fig7){ref-type="fig"}H and 7I), and these cells were characterized by expression of the interferon-stimulated genes (ISGs) (*SIGLEC-1*, *IFI44*, and *IFITM3*) ([Figure 7](#fig7){ref-type="fig"}J), with pathway analyses indicating upregulation of the viral replication and type I IFN signaling pathways. In contrast, the NOS biosynthetic process and monocyte chemotaxis were upregulated in BALF monocytes/macrophages of patients with severe disease ([Figure S7](#figs7){ref-type="fig"}J), which, similar to blood monocytes, expressed lower levels of *HLA-DRA* and *HLA-DRB1* and higher levels of *NFKBIA* mRNA compared with controls or patients with mild COVID-19 ([Figure 7](#fig7){ref-type="fig"}J). Finally, neutrophils were present at high frequencies in BALF from patients with severe COVID-19 but not in BALF from controls or patients with mild disease ([Figures 7](#fig7){ref-type="fig"}K and 7L). UMAP integration of samples from patients with severe disease samples indicated that BALF neutrophils, similar to blood neutrophils ([Figure 7](#fig7){ref-type="fig"}L), were characterized by high expression of *S100A8*, *S100A9*, as well as *CXCR4*, indicating an immature state ([Figures 7](#fig7){ref-type="fig"}M, 7N, and [S7](#figs7){ref-type="fig"}K).

Integration of blood and BALF myeloid cells identified, in patients with severe COVID-19, loss of *HLA-DRA* and *HLA-DRB1* and high *NFKBIA* expression in monocytes/macrophages (not including alveolar macrophages) together with accumulation of neutrophils expressing high levels of *S100A8/A9* and *CXCR4*.

Discussion {#sec3}
==========

This study presents evidence that patients who develop severe COVID-19 exhibit high levels of calprotectin and inflammatory cytokines and chemokines, correlating with emergency myelopoiesis generating ROS- and NOS-expressing immunosuppressive myeloid cells (HLA-DR^Low^ monocytes and immature subsets of neutrophils).

The first line of defense in virus-infected patients typically involves a protective innate response incorporating transient and strong production of type I IFNs. By inducing expression of ISGs, type I IFNs inhibit virus replication and promote an effective innate and adaptive immune response ([@bib56]; [@bib57]). This antiviral response may be impaired in COVID-19 patients who suddenly develop clinically life-threatening disease ([@bib26]). Severe COVID-19 frequently develops in the context of advanced age and comorbidities, which provide a degree of underlying systemic chronic inflammation ([@bib21]). Such inflammation could disrupt the timing of the type I IFN response relative to the kinetics of virus replication ([@bib55]), which has been shown to be critical in mouse models of coronavirus infection ([@bib7]). An imbalance between type I IFN and inflammatory responses could also be favored by the highly efficient replication of SARS-CoV-2 in human tissues ([@bib13]) and by the IFN-neutralizing effects of structural and non-structural viral components shared between SARS-CoV-2 and other virulent human coronaviruses ([@bib9]; [@bib66]).

Patients with severe COVID-19 exhibit abnormal partition of circulating monocytes and of neutrophils expressing the *S100A8* (*calgranulin A/myeloid-related protein 8*) and *S100A9* (*calgranulin B/myeloid-related protein 14*) alarmin genes. Importantly, accumulation of neutrophils expressing high levels of the *S100A8/A9* genes was also observed in the BALF of these patients. The release of massive amounts of calprotectin, the heterodimer formed by S100A8 and S100A9 proteins, is a striking event associated with severe COVID-19. This heterodimer promotes cell migration and boosts NADPH (nicotinamide adenine dinucleotide phosphate) oxidase activity. Calprotectin is a TLR4 and RAGE (receptor for advanced glycation end products) ligand that, upstream of tumor necrosis factor alpha (TNF-α) ([@bib61]) and CXCL8 ([@bib51]) synthesis and secretion, promotes NF-κB activation ([@bib47]) and secretion of multiple inflammatory proteins, such as IL-6 ([@bib63]). Thus, we propose that calprotectin may account for and possibly trigger the cytokine release syndrome that characterizes severe COVID-19. Its production may be amplified by tissue damage, generating a harmful hyperinflammation loop ([@bib34]) that precludes these peptides from exerting more protective functions ([@bib3]; [@bib20]; [@bib58]; [@bib61]). Chronic inflammation from comorbidities may synergize with SARS-CoV-2 infection to induce systemic release of calprotectin, which translates into upregulation of NF-κB and loss of HLA-DR on classical monocytes and the presence of immature neutrophils, converging to a state of chronic inflammation-induced immunosuppression. Abnormal neutrophils have been observed previously in patients with severe COVID-19 ([@bib65]). However, the authors concluded that these neutrophils transdifferentiate from B cells. We have no supporting results suggesting that this could be the case.

Under healthy conditions, roughly 85% of total circulating monocytes are CD14^High^CD16^Low^HLA-DR^High^ cells that are rapidly recruited to inflamed tissues ([@bib25]). As in other severe illnesses ([@bib39]), expression of HLA-DR on CD14^High^ circulating monocytes is low in severe COVID-19, which correlates with, and could be mediated by, IL-6 overproduction ([@bib22]). A more specific feature of COVID-19 is the low fraction of CD14^Low^CD16^High^ non-classical monocytes. This fraction commonly increases in patients with sepsis and inflammatory diseases, including viral infections ([@bib33]). The decrease in non-classical monocyte fraction could involve the ability of calprotectin to hasten *trans*-endothelial migration of leucocytes ([@bib18]), unless these cells strongly adhere to the endothelium or conversion of classical into non-classical monocytes is stuck ([@bib28]; [@bib29]; [@bib48]). Whatever the mechanism, the lower-than-normal frequencies of non-classical monocytes ([@bib56]; [@bib26]) suggest a SARS-CoV-2-characteristic effect that is not observed in other viral infections. Most importantly, this decrease generates a highly characteristic biological signature of COVID-19's aggressive form with the potential to be measured easily using standard diagnostic flow cytometry and provide information regarding the real-time immunological severity of the infection.

The burst of calprotectin detected in COVID-19 patients may trigger NF-κB-driven emergency myelopoiesis, generating immature and dysplastic cells ([@bib4]; [@bib8]). Given the considerable hematopoietic potential of the lungs ([@bib35]), the burst of calprotectin could also promote the contribution of lung megakaryocytes to disease pathogenesis in these organs. Whatever the mechanism, the immature and mature cells released into the peripheral blood by emergency myelopoiesis may be endowed with immunosuppressive functions, suggesting that myeloid-derived suppressive cells (MDSCs), as detected in cancer, inflammation, and other diseases ([@bib60]), might be important in COVID-19. In addition to HLA-DR^Low^ monocytes, whose phenotype is that of monocytic MDSCs (M-MDSCs), CD10^Low^CD101^−^CXCR1^+^ immature cells are reminiscent of granulocytic MDSCs (G-MDSCs) ([@bib1]; [@bib40]; [@bib60]). Thus, neutrophil precursors, such as the pre-neutrophil (preNeu) population, which is CXCR4 positive ([@bib17]), may be released prematurely into the blood from the bone marrow and infiltrate the lung tissue in patients with severe disease. Emergence of these populations could be a predictor of the switch to severe disease. Further research will be required to determine their specific role in disease development.

We observed that severe COVID-19 is specifically associated with (1) a burst of circulating calprotectin that precedes cytokine release syndrome, (2) low levels of non-classical monocytes in the peripheral blood, and (3) emergency myelopoiesis, which releases immature and dysplastic myeloid cells with an immune-suppressive phenotype. Monitoring calprotectin plasma levels and non-classical monocyte in the blood of patients could be implemented routinely in the lab to discriminate patients with early immunological signs consistent with developing more severe disease, as suggested recently ([@bib11]). Finally, in addition to the network of potential drug targets depicted recently by analysis of SARS-CoV-2 interactions ([@bib23]), our work provides a further rationale for testing several clinical strategies, including blocking emergency myelopoiesis with lenzilumab (NCT04351152), a recombinant anti-human granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody ([@bib44]); testing the oral quinoline-3-carboxamide tasquinimod ([@bib19]) and related molecules, such as ABR-215757 (paquinimod), which block binding of S100A9 to TLR4 and RAGE ([@bib31]; [@bib45]); and preclinical anti-CD33 monoclonal antibodies ([@bib62]), which may prevent interaction of S100A9 with myeloid progenitors ([@bib16]).

Limitations of Study {#sec3.1}
--------------------

These analyses provide snapshots of the differences in innate immune cell phenotype and calprotectin plasma levels between outpatients with mild disease at the time of sampling, having no or limited clinical symptoms and not requiring a CT scan or hospitalization, and patients with moderate to severe disease whose clinical situation requires hospitalization and, in most cases, oxygen supply. Although all statistical analyses indicate that these biomarkers efficiently discriminate these two clinical situations and may help with urgent patient triage, a serial analysis is now required to evaluate how these biomarkers can predict the switch from mild to moderate or severe COVID-19 and inform on the mechanisms involved in this switch.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**CD195/CCR5BDCat\# 560635CD10eBiosciencesCat\# 15-0106-42CD101BioLegendCat\# 331010CD117 (ckit)BDCat\# 746848CD11bBDCat\# 740965CD11cBDCat\# 563130CD14BioLegendCat\# 301830CD141BioLegendCat\# 740604CD15BioLegendCat\# 323022CD16BDCat\# 564653CD163BDCat\# 562670CD169BioLegendCat\# 346004CD19BDCat\# 612916CD3BDCat\# 566575CD36BioLegendCat\# 336208CD37BioLegendCat\# 356304CD38BDCat\# 562665CD4BDCat\# 612887CD40BDCat\# 565179CD45BDCat\# 563792CD56BDCat\# 566400CD63BioLegendCat\# 353010CD64R&DCat\# FAB12571N-100UGCD66bBeckman CoulterCat\# IM0531UCD8BDCat\# 563919CD95BDCat\# 740589CD181/CXCR1BioLegendCat\# 320608CD184/CXCR4BioLegendCat\# 306526FcεRIBDCat\# 749338CD130/GP130BioLegendCat\# 362005HLA-DRBDCat\# 561358CD126/IL-6RcBioLegendCat\# 352810CD284/TLR4BDCat\# 564404CD41FluidigmPro\# 3089004BCD45FluidigmPro\# 3141009BCD19FluidigmPro\# 3142001BCD45RAFluidigmPro\# 3143006CCD42FluidigmPro\# 3144020BCD4FluidigmPro\# 3145001BCD8FluidigmPro\# 3146001BCD303FluidigmPro\# 3147009BCD16FluidigmPro\# 3148004BCD34FluidigmPro\# 3149013BCD123/IL-3RFluidigmPro\# 3151001BCD66bFluidigmPro\# 3152011BCD192/CCR2FluidigmPro\# 3153023BCD3FluidigmPro\# 3154003BCD36FluidigmPro\# 3155012BCD10FluidigmPro\# 3156001BCD101FluidigmPro\# 3158020CCD11cFluidigmPro\# 3159001BCD14FluidigmPro\# 3160006BCD90FluidigmPro\# 3161009BCD33FluidigmPro\# 3163023BCD95/FasFluidigmPro\# 3164008BCD163FluidigmPro\# 3165017BPp65/PNFκBFluidigmPro\# 3166006ACD38FluidigmPro\# 3167001BCD71FluidigmPro\# 3168014BCD40BioLegendCat\# 334302CX3CR1FluidigmPro\# 3172017BGranzyme BFluidigmPro\# 3173006CHLA-DRFluidigmPro\# 3174001BCD56FluidigmPro\# 3176008BCD11bFluidigmPro\# 3209003B**Biological Samples**Human blood samplesAPHP-Paris[Tables S1](#mmc1){ref-type="supplementary-material"}--[S3](#mmc1){ref-type="supplementary-material"}, [S4](#mmc2){ref-type="supplementary-material"}, and [S5--S7](#mmc1){ref-type="supplementary-material"}**Chemicals, Peptides, and Recombinant Proteins**CytodelicsCytodelicshC001-1000Cytofix/CytopermBD554714BSAGE Healthcare HycloneSH30574.02EDTASIGMA3690PBSThermoFisher20012068RNase OUT Recombinant Ribonuclease Inhibitor, 40U/mLInvitrogen10777019Chromium Single Cell 3′ Solution v310x GenomicsPN-1000075RNeasy Mini KitQIAGEN74104reverse transcribed with SuperScript IV VILO Master Mix with ezDNase EnzymeInvitrogen11766050Power SYBR GreenApplied Biosystems4368577Foxp3/Transcription Factor Staining Buffer kiteBiosciences00-5523-00Maxpar Cell Acquisition SolutionFluidigm107950EQ BeadsFluidigm201078Bio-Plex Pro^TM^ Human Chemokine Panel 40-plex AssayBio-rad171AK99MR2R-plex Human Calprotectin Antibody SetMeso Scale DiscoveryF21YB-3ultra-sensitive assay S-plex Human IFNa2a kitMeso Scale DiscoveryK151P3S-120-Plex Pd barcoding kitFluidigm201060**Deposited Data**COVID Blood cellsArrayExpress Archive of Functional Genomics DataE-MTAB-9221COVID BALF cells ([@bib37])GEOGSE145926**Oligonucleotides**GUS fowardGAAAATATGTGGTTGGAGAGCTCATTN/AGUS reverseCCGAGTGAAGATCCCCTTTTTAN/AHPRT fowardGGACAGGACTGAACGTCTTGCN/AHPRT reverseCTTGAGCACACAGAGGGCTACAN/AS100A8 fowardCAACACTGATGGTGCAGTTAACTTCN/AS100A8 reverseCTGCCACGCCCATCTTTATCN/AS100A9 fowardCTGAGCTTCGAGGAGTTCATCAN/AS100A9 reverseCGTCACCCTCGTGCATCTTCN/A**Software and Algorithms**Bio-Plex Manager 6.1 SoftwareBio-Rad<https://www.bio-rad.com/fr-fr/product/bio-plex-manager-software-standard-edition?ID=5846e84e-03a7-4599-a8ae-7ba5dd2c7684>CyTOF Software v.6.7.1014Fluidigm<https://www.fluidigm.com/binaries/content/documents/fluidigm/resources/cytof-software-6.7-rl-400314/cytof-software-6.7-rl-400314/fluidigm%3Afile>FlowJo v6.05FlowJo<https://www.flowjo.com/>Cytoscape[@bib50]<https://cytoscape.org/>GraphPad Prism 7GraphPad Software<https://www.graphpad.com/>Ingenuity Pathway Analysis[@bib32]<https://digitalinsights.qiagen.com/products-overview/discovery-insights-portfolio/content-exploration-and-databases/qiagen-ipa/>STAR aligner[@bib15]<https://github.com/alexdobin/STAR>Seurat v3[@bib53]<https://satijalab.org/seurat/install.html>

Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and request for resources and reagents should be directed to and will be fulfilled by the lead contact: <Florent_Ginhoux@immunol.a-star.edu.sg> (F.Gi.).

### Materials Availability {#sec4.2.2}

This study did not generate new unique reagents.

### Data and Code Availability {#sec4.2.3}

All blood scRNA-seq data used in this study can be accessed by ArrayExpress Archive of Functional Genomics Data under the accession number E-MTAB-9221. Integrated BALF scRNA-seq data can be accessed in GEO under the accession number [GSE145926](ncbi-geo:GSE145926){#intref0060}.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Patients {#sec4.3.1}

This non-interventional study was approved by institutional review boards of Cochin-Port Royal (Paris, France) and Gustave Roussy (Villejuif, France) hospitals and the ethical committee of Cochin-Port Royal Hospital (CLEP Decision N°: AAA-2020-08023), and conformed to the principles outlined in the Declaration of Helsinki. Controls (n = 72) were symptomatic patients who were seen at Hôtel-Dieu or Gustave Roussy COVID-19 screening unit and were negative for SARS-CoV-2 RT-PCR on pharyngeal swab. Mild COVID-19 patients (n = 27) were defined by having limited clinical symptoms (fever, cough, diarrhea, myalgia, anosmia/ageusia) that did not require CT-scan or hospitalization. Moderate cases (n = 16) were defined as symptomatic patients with dyspnea and radiological findings of pneumonia on thoracic CT scan, requiring hospitalization and a maximum of 9 L/min of oxygen. In the larger part of this study, mild and moderate cases were analyzed together and grouped under "mild category." Severe patients (n = 43) were those hospitalized in the ICU with respiratory distress requiring 10L/min of oxygen or more, without or with endotracheal intubation and mechanical ventilation.

Method Details {#sec4.4}
--------------

### Sampling {#sec4.4.1}

Whole human peripheral blood was collected into sterile vacutainer tubes containing EDTA or heparin. Except for single cell RNA sequencing, tubes were centrifuged at 300 g for 5 min at room temperature and plasma was collected. Whole blood was mixed at a 1:1 ratio with Whole Blood Cell Stabilizer (Cytodelics), incubated at room temperature for 10 min and transferred to −80°C freezer to await analysis. These samples were secondarily thawed in a water bath set to +37°C. Cells were fixed at a ratio 1:1 with Fixation Buffer (Cytodelics, ratio 1:1) and incubated for 10 min at room temperature. Red blood cells were lysed by addition of 2 mL of Lysis Buffer (Cytodelics, ratio 1:4) at room temperature for 10 min. White blood cells were washed with 2 mL of Wash Buffer (Cytodelics, ratio 1:5).

### Spectral flow Cytometry {#sec4.4.2}

Cells were resuspended in 100 μL extra-cellular antibody cocktail and incubated at room temperature for 15 min. For intra-cellular labeling, a step of permeabilization was performed using 200 μL of BD Cytofix/Cytoperm Kit (BD); cells were then incubated for 40 min at +4°C, washed in Perm Buffer (BD) and resuspended in intra-cellular antibody cocktail. After incubation, cells were washed in Flow Cytometry Buffer (1% BSA, 0.5% Na-Azide and 0.5M EDTA in PBS) and resuspended to proceed to the acquisition. All antibodies are listed in the [Key Resources Table](#sec4.1){ref-type="sec"}. Samples were acquired on CyTEK Aurora flow cytometer (Cytek Biosciences). Fcs files were exported and analyzed using FlowJo software.

### 3′ scRNaseq analysis of human blood cells {#sec4.4.3}

To fully capture peripheral blood cell heterogeneity, we analyzed fresh samples without cell sorting or freezing and without Ficoll enrichment, minimizing time of incubation and processing. Sample preparation was done at room temperature. After red cell lysis, single-cell suspensions were loaded onto a Chromium Single Cell Chip (10x Genomics) according to the manufacturer's instructions for co-encapsulation with barcoded Gel Beads at a target capture rate of ∼7000 individual cells per sample. To analyze neutrophils, we added RNase inhibitor (RNase OUT Recombinant Ribonuclease Inhibitor Invitrogen, 40U/mL) into the loading buffer. Captured mRNAs were barcoded during cDNA synthesis using the Chromium Single Cell 3′ Solution v3 (10x Genomics) according to the manufacturer's instructions. Of note, we increased the PCR cycles by two during cDNA amplification. All samples (at Day 0 and Day 10) were processed simultaneously with the Chromium Controller (10x Genomics) and the resulting libraries were prepared in parallel in a single batch. We pooled all of the libraries for sequencing in a single SP Illumina flow cell. All of the libraries were sequenced with an 8-base index read, a 28-base Read1 containing cell-identifying barcodes and unique molecular identifiers (UMIs), and a 91-base Read2 containing transcript sequences on an Illumina NovaSeq 6000. Reads were aligned to the hg19 genome and were used for subsequent analysis.

### Analysis of scRNaseq and integration of dataset from bronchoalveolar lavage fluid of COVID-19 patients {#sec4.4.4}

Using the package Seurat V3 ([@bib53]), we normalized and scaled scRNA sequencing data. We next applied a principle component analysis to the scRNA sequencing results yielding a number of significant PCs (Using Jackstraw plot analysis). In addition, the standard deviation differences from one PC to another was taken into account as described by the Seurat V3 manual ([@bib53]). To generate UMAP plots, min_distance was set as 0.3 and n_neighbors was set to 30. By dimensionality reduction, distinct clusters were identified and described by performing the FindClusters feature. The resolution of this feature was reduced to 0.3 to identify main cellular population only. Following this, differential genes were identified by performing the FindAllMarkers function and selecting genes that were differentially expressed (logFC \> / = +/− 0.25 and FDR \< 0.05). This approach identified a number of well characterized blood cell populations. Clustering and analysis of specific cell populations were performed in a similar manner to as previously stated. Cells were clustered and separated based on well described markers (CD14/CD16 as describing monocyte populations).

The bronchoalveolar dataset was downloaded from the NIH GEO database (Liao et al., dataset [GSE145926](ncbi-geo:GSE145926){#intref0065}) and integrated with our own blood scRNaseq data using the Seurat V3 anchoring method ([@bib53]). Briefly, the datasets were normalized independently and the highly variable genes were identified for each dataset using the Seurat pipeline. A corrected data matrix with both datasets was then generated using the Seurat v3 anchoring procedure to allow for joint analysis. The matrix was scaled and a Principal Component Analysis (PCA) was performed using the Seurat v3 pipeline. A UMAP was performed on the 30 first Principal Components (PCs) ([@bib5]). These principle components and subsequent clustering and analysis of scRNA sequencing data was performed as previously described.

Comparisons between patient samples were performed by a variation of the FindMarkers function that compared the differentially expressed genes from different samples, patient groups, and organs. Cutoff values were determined as previously described.

### RT-qPCR analysis {#sec4.4.5}

Total RNA was extracted with RNeasy Mini Kit (QIAGEN) and reverse transcribed with SuperScript IV VILO Master Mix with ezDNase Enzyme (Invitrogen). Real-time quantitative polymerase chain reaction (RT-qPCR) was performed using Power SYBR Green PCR Master Mix in a BioRad CFX96 thermocycler using the standard SyBR Green detection protocol as outlined by the manufacturer (Applied Biosystems). Briefly, 12 ng of total cDNA, 50nM (each) primers and 1 × SyBR Green mixture were used in a total volume of 20 μL. Human primer sequences are the following: GUS (F: GAAAATATGTGGTTGGAGAGCTCATT; R: CCGAGTGAAGATCCCCT TTTTA); HPRT (F: GGACAGGACTGAACGTCTTGC; R: CTTGAGCACACAGAGGGCTACA); S100A8 (F: CAACACTG ATGGTGCAGTTAACTTC; R: CTGCCACGCCCATCTTTATC); S100A9 (F: CTGAGCTTCGAGG AGTTCATCA; R: CGTCACCCTCGTGCATCTTC).

### Cytokine and chemokine measurements {#sec4.4.6}

Plasma samples ([Table S6](#mmc1){ref-type="supplementary-material"}) were centrifuged for 15 min at 1,000 g, diluted 1:4, then monitored using the Bio-Plex Pro^TM^ Human Chemokine Panel 40-plex Assay (Bio-rad, ref: 171AK99MR2) according to the manufacturer's instructions. 40-plex cytokines and chemokines provided are: CCL1, CCL11, CCL13, CCL15, CCL17, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL3, CCL7, CCL8, CX3CL1, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL16, CXCL2, CXCL5, CXCL6, CXCL8, CXCL9, GM-CSF, IFNα, IL-10, IL-16, IL-1b, IL-2, IL-4, IL-6, MIF, TNFa. Acquisitions and analyses were performed on a Bio-Plex 200 system (Bio-rad) and a Bio-Plex Manager 6.1 Software (Bio-rad), respectively. Soluble Calprotectin (diluted 1:100) and IFNα2a were analyzed using a R-plex Human Calprotectin Antibody Set (Meso Scale Discovery, ref: F21YB-3) and the ultra-sensitive assay S-plex Human IFNα2a kit (Meso Scale Discovery, ref: K151P3S-1), respectively, following manufacturer's instructions. Acquisitions and analyses of soluble Calprotectin and IFNα were performed on a MESO QuickPlex SQ120 reader and the MSD's Discovery Workbench 4.0. Each plasma sample was assayed twice with the average value taken as the final result. Data representation was performed with software R v3.3.3 using tidyverse, dplyr, ggplot2, ggpubr, pheatmap, corrplot or Hmisc packages.

### Mass Cytometry {#sec4.4.7}

Cells were barcoded using the 20-Plex Pd barcoding kit (Fluidigm). Briefly, they were washed in Barcode Perm Buffer, resuspended in 800 μL of Barcode Perm Buffer and 100 μL of each barcode were transferred to the appropriate sample. Cell suspensions were incubated for 30 min at room temperature, washed twice with Cell Staining Buffer (Fluidigm) and pooled, suspended in 100 μL filtered antibody cocktail, and incubated for 30 min at +4°C. All antibodies used are listed in [Key Resources Table](#sec4.1){ref-type="sec"}. After staining, cells were washed with Cell Staining Buffer and permeabilized with 200 μL of Fix/Perm from Foxp3/Transcription Factor Staining Buffer kit (eBiosciences), 40 min at +4°C. After incubation, cells were washed in Perm Buffer from Foxp3/Transcription Factor Staining Buffer kit (eBiosciences), resuspended in 100 μL filtered antibody cocktail, incubated for 30 min at +4°C, washed in Cell Staining Buffer and resuspended in 50 μL of CytoFix/Perm for 5 min at room temperature. Then, 400 μL of PBS containing 1.6% PFA + Iridium (1:4000) were added for 35 min at room temperature. Finally, cells were washed in Cell Staining Buffer, resuspended in 50 μL and stored at +4°C until acquisition. Cells were counted, washed and resuspended in Maxpar Cell Acquisition Solution at 0.5x 10^6^ / mL and mixed with 10% EQ Beads immediately before acquisition on Helios mass cytometer using noise reduction, event length limits of 10-150 pushes. An average of 500,000 events were acquired per sample at a flow rate of 0.03mL/min. Mass cytometry standard files were normalized to a global standard determined for each log of EQ beads using CyTOF Software v.6.7.1014 (Fluidigm). Fcs files were exported and analyzed using FlowJo software. UMAP was performed with n_neighbors of 15 and a min_distance of 0.2. Clusters were identified by the detection of commonly used cell markers (T cells expressing CD4 or CD8, neutrophils expressing CD15, and monocytes expressing CD14 and or CD16).

### Routine multiparameter flow analysis test {#sec4.4.8}

Whole-blood samples (200μL) were labeled with anti-CD14-PC7 (clone RMO52); CD16-PB (clone 3G8); CD2-FITC (clone 39C1.5); CD56-PC5.5 (clone N901); CD24-PE (clone ALB9); CD45-KO (clone J33) and HLA-DR-APC (clone Immu-357) antibodies, all purchased from Beckman-Coulter. Red blood cells were lysed with 1 mL VersalyseTM (Beckman Coulter) before sample analysis with a Navios Cytometer (Beckman Coulter) as described ([@bib54]). Monocytes were selected as CD45^High^/SSC^Int^ cells among living cells and singlets before excluding T cells as CD2^+^/SSC^Low^, NK cells as CD56^+^/SSC^Low/Int^, B cells as CD24^+^/SSC^Low^, immature and mature granulocytes as CD24^+^/SSC^Int/High^, CD16^Bright^ residual granulocytes, and remaining CD14^−^CD16^−^ cells corresponding mainly to basophils and NK cells not previously excluded. Monocyte subsets were detected on a CD45/SCC dot plot, using a CD14/CD16 scattergram that separates CD14^High^CD16^Low^ (classical), CD14^High^/CD16^High^ (intermediate) and CD14^Low^CD16^High^ (non-classical) subsets. Finally, the proportion of monocytes HLA-DR^Low^ was evaluated on a HLA-DR/CD14 scattergram.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Data analysis {#sec4.5.1}

Calculations and statistical tests were performed using R v3.3.3. Unless stated, p values are two-sided with 95% confidence intervals for the reported statistic of interest. Individual data points representing the measurement from one patient are systematically calculated from the corresponding distribution. Wilcoxon rank-sum test was applied to assess differences in concentration between two different groups. When indicated, the false discovery rate (FDR, p \> 0.05) was controlled using the Benjamini--Hochberg procedure. Spearman correlations were computed using Hmisc R package and cytokine results were shown using R package Pheatmap. Soluble factor fold ratios were calculated as log2 transformation of values of mild and severe patients versus median value of all control patients, and were converted to z scores. Hierarchical clustering of the patients based on the z score of 42 soluble factors was performed using euclidean distance and ward.D clustering. Gene ontology networks were made by subjecting the DEGs from previous scRNA sequencing analysis to the Cytoscape addon ClueGO. The selected DEGs were specific to those with increased expression by monocytes and neutrophils from mild or severe SARS-CoV-2 positive patients. Biological Process gene ontologies selected had an FDR \< 0.05. Other statistical analyses were performed using GraphPad Prism 7.

A generalized linear model was also used to analyze interactions between biological parameters. First, neutrophil count, calprotectin, fibrinogen, IL-6 and D-dimers were normalized using log transformation. Then, calprotectin plasma level was modeled using multivariable linear regression adjusted for the other parameters, and their interaction with the groups. Similar approach was performed to model IL-6. Backward selection was applied to obtain a parsimonious model.

To identify the most discriminant markers, we used a logistic regression adjusted for the scaled log2-transformed markers. Parameters were penalized using the least absolute shrinkage and selection operator (lasso) to limit overfitting due to the high number of markers. The regularization parameter was selected from 10-folds cross-validation using the glmnet R package ([@bib68]). The final AUC estimate was corrected for optimism using the Harrell's method ([@bib69]), and its confidence interval was computed using the two-stage approach proposed by Noma and colleagues ([@bib70]) with 2000 bootstrap samples for each stage. In this analysis, we included age, sex and comorbidities together with biological parameters. Given the absence of validation cohort, AUC was corrected to limit overfitting bias. This correction indicated an AUC at 99.7% (95% confidence interval \[98.8%; 100.0%\]). The final score corresponds to the following equation:$$Score = \frac{1}{1 + \exp\left( {0.272 - 1.530\ C_{1} - 0.013\ \ C_{2} - 0.216\ \ C_{3} - \ 0.212\ C_{4}} \right)}$$With $\ C_{1}$, $C_{2}$, $C_{3}$, and $\ C_{4}$, the values of the calprotectin, CX3CL1, CXCL11 and CXCL13 which are log2 transformed and scaled according to the value training cohort: $C_{1} = \left( {{log2\left( {Calprotectin} \right) - 19.285}/2.278} \right)\ $, $C_{2} = \left( {{log2\left( {CX3CL1} \right) - 7.803}/0.892} \right)$, $C_{3} = \left( {{log2\left( {CXCL11} \right) - 5.503}/1.691} \right)$, and $C_{4} = \left( {{log2\left( {CXCL13} \right) - 5.189}/1.372} \right)$.
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